AD patients: A 20-week Observation Period including 16 weeks of treatment for AD participants and a 4-week follow-up period Healthy subjects: 8 days observation period
Primary Objective:~Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus~Secondary Objectives:~Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus~To evaluate the efficacy of dupilumab in AD participants with chronic pruritus~To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD